Prostate cancer (PC) is a common neoplasm, and metastatic PC remains incurable. The study aims to screen key microRNAs (miRNAs) and transcription factors (TFs) involved in PC.
Introduction
Prostate cancer (PC) is a slowly developed malignancy among men that could become more aggressive in response to androgen blockade. [1] PC is the most prevalent nonskin cancer and the second leading cause of cancer-related deaths in men. [2] Although effective surgical and radiation treatments have been clinically utilized, metastatic PC remains incurable. [3] Better understanding of the molecular mechanism of PC is beneficial for development of novel therapeutic targets. Thus, several studies have been investigated to reveal the molecular mechanisms. For instance, frequent and large-scale genomic rearrangements have been identified in PC tissue. [4] Catechol-O-methyltransferase and glutathione reductase are less active in PC. [5] Sex-steroid hormone, androgens, and estrogens play regulatory roles in PC progression. [6] Testosterone is carcinogenic for rat prostate, as testosterone could be converted to reactive metabolites which adduct to DNA and potentially lead to mutations. [5] Estradiol and estrone are converted to estrogen semiquinones and estrogen quinones which adduct to DNA and redox cycling, producing reactive oxygen species and damaging DNA. [7] Therefore, androgen receptor, enzymes involved in androgens and estrogens metabolism, and DNA repair-related genes are critical for PC progression.
In addition to hormone-related metabolites and genes, microRNAs (miRNAs) also play critical roles in PC progression. MiRNAs are small regulatory RNAs which post-transcriptionally repress the expression of target genes by binding to mRNA sequences and promoting mRNA degradation. [11] Widespread down-regulation of miR-125b, miR-145, and let-7c has been found in human PC tissue. [11] Moreover, it is reported that the target genes of these down-regulated miRNAs are up-regulated in PC tissue, including RAS (p21 ras), E2F transcription factor 3, Bcell lymphoma 2, and myeloid cell leukemia-1. [11] Therefore, screening abnormally expressed miRNAs should be highlighted in the understanding of PC mechanism. Moreover, miRNAs are highly related to the transcription factors (TFs) for the control of gene expressions. The TFs regulate gene expressions at transcriptional level, while the miRNAs at post-transcriptional level. [12] Interestingly, they could be regulated by each other: TF could modulate miRNA-mediated expression via certain pathways; and miRNAs could also regulate the TF-mediated issues to inactivate the target genes. [12] In PC, it is found the miRNAs coordinate with TFs to regulate genes in some transcriptional pathways. [13] However, the direct regulation between miRNAs and TFs are rarely reported. Therefore, we focused on the correlations between miRNAs and TFs in PC progression. In this study, differentially expressed miRNAs (DEmiRNAs) between PC and normal specimens were identified by using bioinformatics tools, and DEmiRNA-DEmiRNA co-regulation network was constructed. Then, DEmiRNA-DEmiRNA functional synergistic network (MFSN) was built based on gene ontology (GO) biological process (BP) functional categories that were enriched by the target genes of DEmiRNAs. Following that, a DEmiRNA-TF regulation network was constructed among the cancer-related TFs and their corresponding DEmiRNAs, and key DEmiRNAs and TFs were identified by analyzing these networks. This study might help researchers to understand the mechanism of PC at molecular level.
Materials and methods

Microarray data
The miRNAs expression profile dataset GSE45604 [14] was downloaded from Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/). The data derived from 60 specimens (10 normal persons and 50 PC patients before treatment) were available based on platform GPL14613 ([miRNA-2_0] Affymetrix Multispecies miRNA-2_0 Array, Affymetrix Inc, Santa Clara, CA). Based on Casanova's description, before tissue collection, the written informed consent was obtained from patients enrolled in the dataset of GSE45604. Additionally, this study was approved by the institutional ethics committee. [14] 
Data preprocessing
According to the annotation file of GPL14613, probe identifiers were converted into miRNA symbols. During this conversion, a probe was removed if it mapped to multiple miRNAs, while if multiple probes corresponded to the same miRNA, their values were averaged to calculate the miRNA expression. Furthermore, miRNAs expression values were normalized through median method.
DEmiRNAs screening
To screen the DEmiRNAs between normal and PC specimens, the Linear Models for Microarray Analysis (limma) package in R (available at http://www.bioconductor.org/packages/release/ bioc/html/limma.html, version: 3.22.1) was utilized, which is the most popular method for differential expression analysis. [15, 16] In the significance analysis, P value was adjusted as false discovery rate (FDR) by Benjamini and Hochberg method. [17] Only the miRNAs met with the criteria of jlog 2 fold change (FC)j > 1 and FDR < 0.05 were defined as DEmiRNAs.
DEmiRNA-target gene prediction
The target genes of DEmiRNAs were explored from 4 databases, including TargetScan (http://www.targetscan.org/), [18] PicTar (http://pictar.mdc-berlin.de/), [19] miRbase (http://www.mirbase. org/), [20] and DIANA-microT (http://diana.cslab.ece.ntua.gr/), [21] predicting potential DEmiRNA-target interactions.
Construction of DEmiRNA-DEmiRNA co-regulation network
DEmiRNAs co-regulating same target gene were identified, based on which a DEmiRNA-DEmiRNA co-regulation network was Figure 1 . Flow chart of the analyses in this study. PC = prostate cancer. constructed and visualized through Cytoscape software (available at http://www.cytoscape.org/, version: 3.2.0). [22] 2.6. Construction of MFSN GO enrichment analysis is a common approach for functional annotation. [23] If co-regulated target genes of 2 (or more) DEmiRNAs were significantly enriched in 1 (or more) GO BP functional term, it is defined that functional synergistic relationships exist between the corresponding DEmiRNAs. To construct an MFSN, DEmiRNA interactions in DEmiRNA-DEmiRNA co-regulation network were ranked according to the numbers of their co-regulated target genes. Thereafter, the target genes co-regulated by the top 30 DEmiRNA pairs were put through GO BP functional enrichment analysis by clusterProfiler package in R (available at http:// bioconductor.org/packages/release/bioc/html/clusterProfiler.html, version: 2.0.0), [24] and the criteria for significant BP terms were P < 0.05 and q < 0.05. Moreover, based on functional enrichment results, DEmiRNA interactions sharing 1 (or more) GO BP functional term were utilized to construct MSFN, which was further visualized through Cytoscape software.
Construction of DEmiRNA-TF regulation network and subnetwork
Comprising of eukaryotic TFs, TFs target genes, and regulatory binding sites, the TRANSFAC database (http://www.generegulation.com/index2) has been established and well developed. [25] According to TRANSFAC database and Transcriptional Regulatory Element Database (TRED, https://cb.utdallas.edu/ cgi-bin/TRED/tred.cgi?process=home), [26] cancer-related TFs were screened out to build DEmiRNA-TF regulation network, 
Results
The process of analyses in our study is presented in Fig. 1 . Table 2 .
Construction of DEmiRNA-DEmiRNA co-regulation network
Based on the numbers of co-regulated target genes, a DEmiRNA-DEmiRNA co-regulation network was constructed, involving 66 nodes (DEmiRNAs), 2024 edges (co-regulation relationships), and 11,086 co-regulated target genes (Fig. 2) . In this network, there were strong relationships between hsa-miR-875-3p, hsa-miR-4328, hsa-miR-24, and hsa-miR-31; hsa-miR-338-5p and hsa-miR-543; hsa-miR-24 and hsa-miR-1184; hsamiR-24 and hsa-miR-1207-5p; etc. Especially, hsa-miR-24 was down-regulated, whereas hsa-miR-1184 and hsa-miR-1207-5p were up-regulated, which shared 1321 and 1230 target genes with hsa-miR-24, respectively. Additionally, hsa-mir-875-3p was tightly linked to hsa-mir-4328 in the network, and both of them were down-regulated (Fig. 2) .
Construction of DEmiRNA-DEmiRNA functional synergistic network
After GO BP functional enrichment analysis with the aforementioned criteria (P < 0.05, q < 0.05), significant functional synergistic relationships were identified among the top 30 DEmiRNA interactions with most co-regulated target genes in Fig. 2 . Then, MFSN was constructed (Fig. 3) . In addition, 693 significant GO BP terms were enriched by the co-regulated target genes of hsa-miR-1207-5p and hsa-miR-24, and 862 significant BP terms were enriched by the co-regulated target genes of hsamiR-1184 and hsa-miR-24. Apparently, hsa-miR-1184, hsamiR-1207-5p, and hsa-miR-24 had significant functional synergistic relationships.
Construction of DEmiRNA-TF regulation network and subnetwork
Using the information in TRANSFAC database, 331 TFs were predicted to regulate the 11,086 co-regulated target genes. Further, according to the information of 36 cancer-related TF families in TRED database, 52 of the 331 TFs belonged to 28 cancer-related TF families (Table 3) . Then, regulation network was constructed between the 52 cancer-related TFs and their corresponding DEmiRNAs (Fig. 4) . Considering miRNAs often suppress gene or TF expressions by targeting them, increased miRNAs might have more important roles in cancer development. Therefore, we mainly focused on the up-regulated DEmiRNAs. Among the 7 identified DEmiRNAs, 6 were exhibited in this network. As hsa-miR-1207-5p and hsa-miR-1184 both had the co-regulation relationship with the down-regulated hsa-miR-24 (Fig. 3) ; and hsa-miR-182 and hsamiR-183 had been implicated in PC or other cancer types, [14, 27, 28] the 4 DEmiRNAs were further extracted to construct subnetwork (Fig. 5) . It is found that the TFs of peroxisome proliferative activated receptor, alpha (PPARA) and cyclic AMP-responsive element modulator (CREM) were 2 critical nodes with the highest degree (=4), which indicated both of them were interplayed with the 4 up-regulated DEmiRNAs.
Discussion
PC is a prevalent cancer, whose occurrence and development is a complex process. Comprehensive analysis of miRNAs and TFs related to PC will help us to understand the molecular mechanism of PC and develop novel therapeutic targets for its treatment. In this study, we identified 66 significant DEmiRNAs between normal and PC specimens and their coregulated cancer-related TFs through bioinformatics analysis. It Table 3 The 52 cancer-related transcription factors regulated by differentially expressed miRNAs. Degree represented the number of corresponding DEmiRNAs.
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was predicted that 4 up-regulated DEmiRNAs (hsa-miR-1207-5p, hsa-miR-1184, hsa-miR-182, and hsa-miR-183) and 2 of their co-regulated target TFs (PPARA and CREM) might participate in PC. In addition, 2 down-regulated DEmiRNAs, hsa-mir-875-3p and hsa-mir-4328 were also important for their strong relationships in the co-regulation network. Among these DEmiRNAs, hsa-miR-1207-5p and hsa-miR-1184 shared more than 1200 target genes with hsa-miR-24, which enhances breast tumor metastasis and invasion by targeting PTPN9 and PTPRF, and promoting EGF signaling. [29] In addition, miRNA-24 is one of the most abundant miRNAs in cervical cancer cells, and it is reported to be up-regulated in solid stomach cancers. [29] It seems like hsa-miR-24 plays vital roles in various cancers. In PC, miR-24 is found to modulate apoptosis in the DU-145 cell lines, via targeting to the coding sequence region of fas associated factor 1.
[30] Therefore, we speculated that it may be involved in PC progression. As large amount of target genes and GO BP terms were shared by hsa-miR-1184 and hsa-miR-1207-5p with hsa-miR-24, hsa-miR-1184 and hsa-miR-1207-5p might also play a role in the development of PC, and they might be used as potential targets for the treatment of PC. In addition, it is reported that hsa-miR-182-5p promotes cell proliferation, migration, and invasion by down regulating forkhead box F2, reversion-inducing cysteine-rich protein with Kazal motifs, and metastasis suppressor 1 in human PC, and the knock-down of miR-182-5p with its inhibitor significantly decreased prostate tumor growth. [31] Moreover, hsa-miR-183 is an oncogenic miRNA targeting dickkopf 3 homolog (DKK3) and drosophila mothers against decapentaplegic family member 4 (SMAD4) in PC. [27] The high expression of hsa-miR-183 was correlated with high pathological (pT) stage and short overall survival time of PC patients, and the knockdown of hsa-miR-183 significantly decreased cell proliferation, motility, and prostate tumor growth. [27] In this study, hsa-miR-182 and hsa-miR-183 were significantly up-regulated in PC tissue, coinciding with previous studies. Therefore, these DEmiRNAs might be key regulators in PC progression, and they might be used as potential targets for the treatment of PC.
Regarding to the down-regulated DEmiRNAs, hsa-miR-875-5p is predicted to be associated with different PC tumor status. [32] Inconsistent with our findings in PC, in other cancer types such as intrahepatic cholangiocarcinoma and esophageal cancer, expression of hsa-miR-875-3p is increased in tumor groups compared with normal control. [33, 34] This prompts us the down-regulation of hsa-miR-875-3p might be specific in PC, and could be used as a novel indicator for the disease progression. However, its detailed functions should be investigated by further studies. Currently, only a few studies reported the alteration of hsa-mir-4328 in cancers. In mucinous cystadenocarcinoma, hsa-mir-4328 is significantly decreased compared with the mucinous cystadenoma. [35] In addition, it is also down-regulated in keloid fibroblasts. [36] Nevertheless, dysregulation of this miRNA has not been reported in PC yet. Thus, based on our study, it might be inferred down-regulation of hsa-mir-4328 may be a novel biomarker for PC progression.
The DEmiRNA-TF regulation network displayed that PPARA and CREM were co-regulated by 4 up-regulated DEmiRNAs. CREM can bind to c-fos CRE and heterodimerize with CREbinding protein, which could block cAMP induction and cAMPinduced apoptosis of germ cells. [27] In this study, CREM was found to be co-regulated by 4 DEmiRNAs, which might influence apoptosis and carcinogenesis in PC cells. However, no current studies have reported the regulation between this gene and the 4 miRNAs. PPARA is a peroxisome proliferator-activated receptor, which regulates key genes involved in fatty acid oxidation, extracellular lipid metabolism, hemostasis, and inflammation. [37] It is demonstrated that the up-regulation of PPARA and its downstream targets leads to increased lipogenesis, which slows cell growth and tumor progression. [38] In this study, the significant upregulation of 4 DEmiRNAs might collectively decrease PPARA mRNA, promoting cell growth and tumor progression. However, these targeting relationships need to be further validated.
What is more, conflicts between DEmiRNAs co-regulating the same gene also exist. Nuclear factor of kappa light polypeptide (NFKB1) was presented in DEmiRNA-TF regulation subnetwork. NFKB1 is associated with colorectal cancer. [39] Constitutive NFKB activation was observed in 40% of colorectal cancer tissues. [40] In this study, NFKB1 was co-regulated by hsa-miR-183 and hsa-miR-338-5p, which were significantly up-regulated and down-regulated in PC tissue, respectively. Therefore, it is predicted that the balance between hsa-miR-183 and hsa-miR-338-5p might play a role in PC through co-regulating NFKB1. Moreover, cyclooxygenase 2 (COX2) is a key enzyme in the biosynthesis of prostaglandins, which promote inflammation. [41] Additionally, COX2 promotes cell proliferation and growth, and its overexpression is often found in tumor tissues. [42] The activation of P2Y2/Src/p38/COX2 pathway induces resistance to apoptosis in PC cells. [42] It is reported that miR-101 could inhibit COX2 expression post-transcriptionally, and exogenous miR-101 could effectively suppress PC cells growth, providing a new therapy for PC treatment. [43] In this study, COX2 is co-regulated by both up-regulated and down-regulated DEmiRNAs, like hsamiR-490-5p, hsa-miR-509-3-5p, hsa-miR-143, hsa-miR-628-3p, hsa-miR-182, and hsa-miR-183, indicating that the balance between these DEmiRNAs might play a role in PC through coregulating COX2. Researches on miRNAs and TFs are fascinating for human to understand and recognize the mechanism of cancers and further develop new therapeutic strategies for cancers. The miRNAs and TFs found in our research might co-regulate PC and thus serve as new therapeutic targets for PC treatment. But more in vivo researches are needed, and we plan to validate the results of this study by using real-time PCR and dual-luciferase reporter assay in the future study. In addition, it will be useful to further analyze the dynamic changes of miRNA expression along the progression of PC using specimens from patients with different pT stage or Gleason score, and we plan to perform this analysis in the future.
